The Harvard spinout plans to use the proceeds to expand its service offerings, and to seek partnerships with researchers and hospitals around the world.
ReadCoor is currently using its its technology to map neural circuits in the brain and has projects in the pipeline related to oncology and infectious disease.
The funds will support Cyclica's sales and marketing efforts and development of its drug-protein interaction analysis software product.
The startup, which was founded in 2015 by former BGI employees, is developing next-generation sequencing tests for cancer applications.
The company said it will use the funds to further develop its DNA search technologies based on the Taxonomer pathogen metagenomics analysis platform.
The funding will be used to support Appistry's operations and engineering efforts, including the continued development of its GenomePilot DNA data-analysis software.
As LDT developers await an FDA decision on potential new regulations and grapple with reimbursement issues, investors may be unwilling to deal with the uncertainty.
The company said it will use the proceeds to develop and commercialize its pipeline of metabolomics-based products.
The firm plans to use the funds to support ongoing clinical trials, as well as development and commercialization of its full range of tests.
N-of-One will use the funds to develop new oncology clinical decision support solutions, and to expand its sales and marketing efforts.
The Wall Street Journal speaks with patients affected by questionable test results from Theranos.
Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.
Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.
In Science this week: convergent evolution in bird hemoglobin, and more.